Therapeutic Targeting of Malignant Glioma

Author(s): Daniela Alexandru-Abrams, Martin R. Jadus, Frank P. Hsu, Apostolos Stathopoulos, Daniela A. Bota

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 14 , Issue 8 , 2014

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Glioblastoma Multiforme (GMB) is the most aggressive primary brain tumor with poor survival rates and universal recurrence despite aggressive treatments. Recent research suggested that GBM has multiple glioma cell populations, some of which are organized in a stem cell hierarchical order with different stages of differention. Evidence indicated that recurrence is due to a development or persistance of a subpopulation of these tumor cells which are inherently resistant to treatment and these were defined as the glioma stem-like cells (GSC). It is hypothesized that GSC become highly malignant by accumulating mutations in oncogenic pathways. These cells present with specific surface markers which helps identify them. Targeting the surface markers as well as the signaling pathways of GSCs has been an ongoing research effort. This review focuses on summarizing the current treatment modalities used to glioblastoma treatments, evaluating their efficacy in controlling and eradicatig the GSCs, discussing the machanisms involved in GSC tumor proliferation and resistance to treatments in addition to proposing potential avenues to target GSCs in order to provide a potential cure for this cancer.

Keywords: chemotherapy, glioma stem cells, immunotherapy, malignant glioma, treatment resistance.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 05 September, 2014
Page: [1075 - 1084]
Pages: 10
DOI: 10.2174/1871520614666140825105145
Price: $65

Article Metrics

PDF: 59